Aurinia Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: AUPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Aurinia Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Aurinia Pharmaceuticals generated $52.6 million of operating cash flow. That left free cash flow of $52.6 million, a free-cash-flow margin of 63.2% of revenue. Free cash flow was up 18.8% from the prior year's $44.2 million.
Aurinia Pharmaceuticals returned $38.7 million to shareholders through share repurchases, equal to 74% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Aurinia Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 37.41M | 34.35M | 210.79M | 31.55M | 21.51M | 23.34M | 1.43M | 14.35M | 722.00K | -10.75M | -26.88M | -13.45M |
| Net Income growth (YoY) | +73.91% | +47.17% | +14651.15% | +119.87% | +2879.64% | — | — | — | — | — | — | — |
| Depreciation & Amortization | 4.83M | 4.82M | 4.86M | 4.87M | 4.86M | 4.86M | 4.86M | 4.89M | 4.84M | 4.85M | -6.10M | 5.26M |
| Stock-Based Compensation | 2.84M | -866.00K | 6.73M | 5.92M | 5.44M | -3.41M | 8.95M | 8.33M | 8.59M | 5.74M | 11.77M | 11.81M |
| Change in Working Capital | 7.12M | -8.01M | -11.01M | 8.98M | -145.00K | -7.41M | 1.00M | -9.19M | 6.40M | -3.53M | 8.55M | -8.46M |
| Operating Cash Flow | 52.57M | 32.56M | 45.67M | 44.45M | 44.24M | 1.30M | 30.11M | 17.03M | 15.84M | -18.60M | 14.31M | -13.28M |
| Investing Cash Flow | 81.45M | -18.08M | -36.76M | -13.77M | -13.27M | 31.03M | 39.22M | -10.57M | -38.62M | 49.23M | -6.26M | -19.70M |
| Share Repurchases | -38.72M | -36.16M | 0 | -8.67M | -42.56M | -46.92M | -21.80M | 0 | -6.13M | -12.30M | 0 | 0 |
| Financing Cash Flow | 4.81M | -53.69M | -1.89M | -10.49M | -44.39M | -49.34M | -23.05M | -2.72M | -8.27M | -15.05M | -5.58M | -2.33M |
| Net Change in Cash | 138.82M | -39.20M | 7.02M | 20.19M | -13.43M | -17.00M | 46.29M | 3.73M | -31.05M | 15.58M | 2.48M | -35.31M |
| Free Cash Flow | 52.57M | 32.56M | 45.67M | 44.45M | 44.24M | 1.30M | 30.11M | 17.03M | 15.84M | -18.60M | 14.31M | -13.28M |
This table shows 12 quarterly periods of Aurinia Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AUPH's reporting calendar. What is a cash flow statement?